News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
260,153 Results
Type
Article (13549)
Company Profile (110)
Press Release (246494)
Section
Business (87934)
Career Advice (460)
Deals (15326)
Drug Delivery (63)
Drug Development (36518)
Employer Resources (49)
FDA (6259)
Job Trends (6181)
News (149996)
Policy (14005)
Tag
Academia (435)
Alliances (23071)
Alzheimer's disease (340)
Approvals (6247)
Artificial intelligence (54)
Bankruptcy (143)
Best Places to Work (4274)
Biosimilars (36)
Biotechnology (44)
Breast cancer (33)
Cancer (254)
Career advice (403)
Cell therapy (36)
Clinical research (30243)
Collaboration (109)
Compensation (51)
COVID-19 (746)
C-suite (32)
Data (229)
Diabetes (42)
Diagnostics (1223)
Drug pricing (54)
Earnings (31238)
Employer resources (43)
Events (36483)
Executive appointments (134)
FDA (6398)
Funding (81)
Gene therapy (55)
GLP-1 (283)
Government (1259)
Healthcare (3514)
Infectious disease (762)
Inflammatory bowel disease (45)
Interviews (57)
IPO (5794)
Job creations (2048)
Job search strategy (371)
Layoffs (166)
Legal (3407)
Lung cancer (40)
Manufacturing (75)
Medical device (1257)
Medtech (1259)
Mergers & acquisitions (9520)
Metabolic disorders (142)
Neuroscience (424)
NextGen Class of 2024 (1578)
Non-profit (589)
Northern California (336)
Obesity (91)
Opinion (107)
Patents (49)
People (28362)
Pharmaceutical (64)
Phase I (7863)
Phase II (12785)
Phase III (11497)
Pipeline (82)
Podcasts (38)
Policy (41)
Postmarket research (1399)
Preclinical (3151)
Radiopharmaceuticals (116)
Rare diseases (69)
Real estate (2630)
Regulatory (9784)
Research institute (562)
Resumes & cover letters (55)
Southern California (351)
Startups (1624)
United States (3427)
Vaccines (106)
Weight loss (72)
Date
Today (54)
Last 7 days (199)
Last 30 days (924)
Last 365 days (12931)
2024 (10462)
2023 (14244)
2022 (19570)
2021 (20076)
2020 (19038)
2019 (14887)
2018 (11714)
2017 (13890)
2016 (13130)
2015 (15474)
2014 (12423)
2013 (10594)
2012 (11398)
2011 (11925)
2010 (10890)
Location
Africa (312)
Arizona (37)
Asia (19720)
Australia (2546)
California (781)
Canada (528)
China (87)
Connecticut (33)
Europe (38612)
Florida (112)
Illinois (87)
Indiana (72)
Kansas (50)
Maryland (123)
Massachusetts (692)
Minnesota (46)
New Jersey (329)
New York (226)
North Carolina (254)
Northern California (336)
Ohio (35)
Pennsylvania (239)
South America (498)
Southern California (351)
Texas (108)
Washington State (58)
260,153 Results for "cadila pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
Enzychem to Partner with Zydus Cadila to Manufacture COVID-19 Plasmid DNA Vaccine in Korea
Enzychem Lifesciences and Cadila Healthcare Ltd, a part of the Zydus Group, announced that they have entered a Manufacturing License and Technology Transfer Agreement for the world’s first plasmid DNA vaccine.
November 26, 2021
·
3 min read
BioMidwest
PharmaJet partner Zydus Cadila Announces COVID-19 Vaccine Expansion Plan to Multiple Countries With Korean Firm
PharmaJet®, the maker of innovative, needle-free injection technology, announced that its partner Zydus Cadila, is partnering with Enzychem Lifesciences to manufacture their COVID-19 plasmid DNA vaccine in Korea.
January 4, 2022
·
3 min read
PharmaJet Partner Zydus Cadila Seeks EUA on World’s First Plasmid DNA COVID-19 Vaccine
PharmaJet®, the maker of innovative, needle-free injection technology, today announced that its partner Zydus Cadila has applied for Emergency Use Authorization (EUA) to the office of the Drug Controller General of India (DCGI) for its plasmid DNA Vaccine against COVID-19.
July 7, 2021
·
3 min read
Business
Fennec Pharmaceuticals Announces Management Change
Fennec Pharmaceuticals Inc., a commercial stage specialty pharmaceutical company, announced that Adrian Haigh has departed from his position as Fennec’s Chief Operating Officer as of June 30, 2024.
July 1, 2024
·
4 min read
PharmaJet Partner Zydus Cadila Announces Emergency Use Authorization Approval for World’s First Plasmid DNA COVID-19 Vaccine
PharmaJet®, the maker of innovative, needle-free injection technology, today announced that its partner, Zydus Cadila, has received the Emergency Use Authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D the world’s first Plasmid DNA Vaccine for COVID-19.
August 23, 2021
·
3 min read
Deals
Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 Billion
Deciphera Pharmaceuticals, Inc. today announced that it has entered into a definitive merger agreement with ONO Pharmaceutical Co., Ltd.
April 29, 2024
·
10 min read
BioMidwest
Aurorium Launches Haelium™ Pharmaceutical Solutions
Aurorium, a specialty ingredients manufacturer and materials innovation partner, is pleased to announce the launch of Haelium™ Pharmaceutical Solutions.
June 25, 2024
·
2 min read
Press Releases
Acella Pharmaceuticals, LLC, an Alora Pharmaceuticals, LLC Subsidiary, Partners with Paloma Health for Hypothyroidism Patients
October 23, 2024
·
2 min read
High Potency Active Pharmaceutical Ingredients Market Size, Growth, Report 2024-2033
According to Vision Research Reports, the global high potency active pharmaceutical ingredients market size was valued at USD 26.75 billion in 2023 and it is expected to surpass around USD 49 billion by 2033 with a CAGR of 6.24% from 2024 to 2033.
April 22, 2024
·
8 min read
Deals
Cycle Pharmaceuticals Announces All-Cash Proposal to Acquire Vanda Pharmaceuticals for $8.00 Per Share
Cycle Pharmaceuticals Ltd today confirmed that it made a proposal to the Board of Directors of Vanda Pharmaceuticals, Inc. (“Vanda”) (NASDAQ: VNDA) on May 24, 2024 to acquire 100% of Vanda’s issued and outstanding shares for a cash consideration of $8.00 per Vanda share, representing a total cash consideration of $466 million.
June 6, 2024
·
5 min read
1 of 26,016
Next
